Pfizer's API business revenue falls 13% on lower international sales

By Gareth Macdonald

- Last updated on GMT

iStock/Carther
iStock/Carther

Related tags Revenue Pfizer

Revenue generated by Pfizer’s API and contracting business fell in the second quarter.

The US drug firm’s contract manufacturing business – Pfizer CentreOne - generated $171m (€144m) in the three months to the end of June, down 13% on the year earlier quarter.

In the US, CentreOne – which is a unit of Pfizer’s Essential Health division - generated revenue of $132m, which is up $1m from the contribution in Q2 last year. In contrast, in international markets, the unit brought in $39m, down 39%.

The decline continues the trend seen in Q1 when the CentreOne unit’s revenue fell 8% to $182m as a result of lower international sales.

Pfizer’s total revenue for the second quarter was down 2% at $12.9bn.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars